Treatment of Active CLL with Unmutated IGHV in Medically Unfit Patients (No TP53 Mutation, No del(17p))

This protocol addresses a specific population: patients with active chronic lymphocytic leukemia who carry unmutated IGHV status, have no TP53 mutation, no del(17p) chromosomal deletion, and who are not medically fit due to significant comorbidity.

Clinical Scenario

This patient profile is defined by:

Active CLL requiring first-line treatment
Unmutated IGHV gene status
Absence of TP53 mutation
Absence of del(17p) chromosomal deletion
Medical unfitness due to significant comorbidity

Treatment Approach

First-Line Protocol

Evidence-based first-line management for this population incorporates venetoclax-based combination therapy among other structured regimen options — the selection between available approaches depends on patient-specific factors outlined in the full protocol.

The complete set of regimen options, decision criteria, and the full treatment algorithm are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

CLL with unmutated IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies):
Unfit patients: venetoclax plus obinutuzumab or ibrutinib or acalabrutinib [I, A] or chlorambucil plus obinutuzumab.

View source ↗